REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage pharmaceutical company focused on developing treatments for central nervous system disorders and metabolic diseases, including schizophrenia and Parkinson's disease. The company filed an S-1/A registration statement amendment with the SEC on January 7, 2021, accession number 0001104659-21-002049, as part of its path to becoming a publicly traded entity via a SPAC transaction around the turn of 2021. RVPH operates in the healthcare and biopharmaceutical sector, with its pipeline centered on novel small-molecule drug candidates targeting dopamine and serotonin receptor pathways. Investors and analysts tracking de-SPAC healthcare names can access the full filing history, sponsor details, and deal metrics for RVPH and hundreds of similar transactions by signing up for complete data at SpacDesk.